Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
dasatinib (sprycel) (1 trial)
fulvestrant (faslodex) (1 trial)
mk-0646 (1 trial)
Breast Neoplasms (Phase 2)
Trials (1 total)
Trial APIs (3 total)